NCT03007030View on ClinicalTrials.gov

Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

PHASE2RecruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

April 5, 2017

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2026

Conditions
CD30-Positive Neoplastic Cells PresentMalignant Mesothelioma
Interventions
DRUG

Brentuximab Vedotin

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER